A next-generation CAR-T cell therapy targeting Claudin18.2 has demonstrated remarkable clinical results in patients with advanced gastric cancer and gastroesophageal junction (GEJ) cancer, marking a significant step forward in solid tumor immunotherapy.
This innovative therapy utilizes nanobody technology (VHH) derived from camelid antibodies as its antigen-recognition domain. Compared to traditional single-chain variable fragment (scFv)-based CAR-T therapies, this approach introduces several transformative advantages.
Key Advantages of Nanobody-Based CAR-T
1. Enhanced Precision
Nanobodies are approximately one-third the size of conventional scFv antibodies, enabling better penetration into the tumor microenvironment. This allows for more accurate targeting of Claudin18.2-positive cancer cells while minimizing damage to normal gastric tissues.
2. Reduced T Cell Exhaustion
The VHH structure reduces nonspecific clustering of CAR molecules on T cells, lowering baseline activation signals (tonic signaling). This helps delay T cell exhaustion and improves both the durability and effectiveness of the anti-tumor response.
3. Improved Safety Profile
Preclinical studies suggest a significantly lower risk of on-target, off-tumor toxicity compared to traditional CAR-T designs, supporting its potential for broader application in solid tumors.
Promising Clinical Results
Results from a Phase I/IIa clinical study presented at a major gastrointestinal oncology conference revealed impressive safety and efficacy outcomes:
Favorable Safety
- Among 16 treated patients, no Grade 3 or higher cytokine release syndrome (CRS) was observed
- No neurotoxicity (ICANS) or treatment-related deaths reported
- All adverse events were Grade 1–2 and manageable
- Safety profile appears superior to many existing CAR-T therapies
Strong Efficacy
- 15 evaluable patients:
- 10 achieved objective response
- Objective Response Rate (ORR): 66.7%
- Median progression-free survival (mPFS): 7 months
- Median overall survival (mOS): 10.3 months
- Outcomes exceed those typically seen in later-line standard therapies
Durable Complete Remission in Advanced Disease
A particularly notable case involved a patient with metastatic gastroesophageal junction cancer who had failed multiple prior treatments. After receiving this CAR-T therapy:
- Liver and anastomotic lesions completely disappeared
- The patient achieved complete remission (CR)
- Remission has been sustained for over 60 weeks (more than 1 year)
- No signs of recurrence have been observed to date
Expert Perspective
According to leading clinical investigators, the deep and durable responses observed in heavily pretreated patients provide critical evidence supporting the use of Claudin18.2-targeted CAR-T therapy in solid tumors.
The therapy’s favorable safety profile further suggests potential for expansion into earlier lines of treatment.
A New Direction for Solid Tumor CAR-T Therapy
Claudin18.2 has emerged as one of the most promising targets in gastric and GEJ cancers. This study highlights how next-generation CAR-T engineering—particularly nanobody-based designs—may overcome longstanding challenges in treating solid tumors.
As research progresses into later-stage trials, this approach could redefine treatment options for patients with advanced gastrointestinal cancers worldwide.
